Dapoxetine hydrochloride , ≥98%(HPLC) , 129938-20-1

CAS NO.：129938-20-1

Empirical Formula: C21H23NO·HCl

Molecular Weight: 341.88

MDL number: MFCD08272809

EINECS: 640-411-8

PRODUCT Properties

• Melting point: 175-1790C
• alpha: D +135.78° (c = 2.18 in methanol)
• storage temp.: room temp
• solubility: DMSO: ≥20mg/mL
• form: powder
• color: white
• optical activity: [α]/D +125 to +135°, c = 1 in methanol
• Merck: 14,2821
• InChI: InChI=1/C21H23NO.ClH/c1-22(2)20(18-10-4-3-5-11-18)15-16-23-21-14-8-12-17-9-6-7-13-19(17)21;/h3-14,20H,15-16H2,1-2H3;1H/t20-;/s3
• InChIKey: IHWDIQRWYNMKFM-OZYVVJTJNA-N
• SMILES: O(C1=CC=CC2C=CC=CC1=2)CC[C@@H](C1C=CC=CC=1)N(C)C.Cl |&1:13,r|

Description and Uses

Dapoxetine hydrochloride, belonging to the class of SSRIs, was the first drug originally approved for the on-demand treatment of men with PE by seven European countries in 2008.
Premature ejaculation (PE) is the most common male sexual dysfunction. Dapoxetine is a short-acting SSRI. It is differentiated from the existing SSRI treatments for PE by the fact that it can be administered on an as-needed basis. In healthy subjects, dapoxetine is rapidly absorbed after oral administration with a peak plasma concentration (Tmax) occurring between 1.4 and 2h.

Dapoxetine hydrochloride is a short-acting novel selective serotonin reuptake inhibitor marketed for the treatment of premature ejaculation in men. Premature ejaculation (PE) is the most common male sexual disorder, estimated to affect up to 30% of men.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H319-H413
• Precautionary statements: P305+P351+P338
• Hazard Codes: Xn,N
• Risk Statements: 22-36-50/53
• Safety Statements: 36-60-61
• RIDADR: UN 3077 9 / PGIII
• WGK Germany: 3
• HS Code: 29221990